Genetic Variations in Two Genes Linked to Weight Loss and Side Effects from GLP-1 Drugs

Variations in two genes related to appetite regulation and digestion help predict which patients will experience substantial weight loss from GLP-1 drugs, according to a new study. GLP-1 drugs, such as semaglutide and liraglutide, are commonly prescribed for obesity and type 2 diabetes. The research, published in a peer-reviewed journal, analyzed genetic data from patients undergoing treatment.

Patients carrying specific genetic variations lost more weight compared to those without them. STAT News reported that these changes also predict a higher likelihood of gastrointestinal side effects, including nausea and vomiting. The study involved hundreds of participants, with genetic testing conducted prior to treatment initiation.

The research examined the role of genes influencing hunger signals and gut motility.

Both sources agree that individuals with the variations achieved an average weight loss of 15-20% of body weight over 12 months, versus 8-10% in others. No contradictions appear in the reported genetic associations. STAT News detailed that the genes are SLC6A4, linked to serotonin transport and appetite, and ADRA2A, involved in adrenergic signaling for digestion.

The study controlled for factors like dosage and patient demographics. Researchers emphasized the need for larger trials to confirm results.

“Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.”

These findings could enable genetic screening to identify optimal candidates for GLP-1 therapy. BBC News noted that the drugs, often administered as weekly injections, have transformed obesity management since their approval in the 2010s. Side effects like nausea affect up to 40% of users, potentially reducing adherence.

The study suggests tailoring treatments based on genetics might improve outcomes and minimize adverse reactions. Ongoing research explores similar predictors for other metabolic drugs. Clinical guidelines may incorporate genetic testing in the future.

receptor agonists mimic hormones that regulate blood sugar and appetite. They slow gastric emptying and signal fullness to the brain. Approved by the FDA for weight management in 2014, these drugs have been used by millions worldwide. Obesity affects over 1 billion people globally, per World Health Organization data.

The genetic insights build on prior studies showing variable responses to pharmacotherapy. No sources reported funding conflicts in this research.